Enanta Pharmaceuticals traded at $49.63 this Friday July 1st, increasing $2.36 or 4.99 percent since the previous trading session. Looking back, over the last four weeks, Enanta Pharmaceuticals gained 19.53 percent. Over the last 12 months, its price rose by 12.29 percent. Looking ahead, we forecast Enanta Pharmaceuticals to be priced at 48.29 by the end of this quarter and at 44.46 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 153.80 0.64 0.42% 33.54%
Acorda Therapeutics 0.48 0.01 3.20% -89.34%
Amgen 245.55 2.25 0.92% -1.27%
Anika Therapeutics 22.51 0.19 0.85% -49.04%
Arrowhead Research 35.96 0.75 2.13% -43.04%
AstraZeneca 10,820.00 12.00 0.11% 24.07%
BioCryst Pharmaceuticals 10.84 0.26 2.46% -34.22%
Biogen 210.63 6.69 3.28% -39.60%
Bristol-Myers Squibb 76.84 -0.16 -0.21% 14.77%
Clovis Oncology 2.85 1.05 58.33% -49.91%
Enanta Pharmaceuticals 49.63 2.36 4.99% 12.29%
Gilead Sciences 62.36 0.55 0.89% -10.01%
GlaxoSmithKline 1,797.20 -5.40 -0.30% 25.31%
Halozyme Therapeutics 44.48 0.48 1.09% -4.18%
Heron Therapeutics 2.72 -0.07 -2.51% -81.71%
Intercept Pharmaceuticals 14.13 0.32 2.32% -29.31%
Incyte Corp 77.67 1.70 2.24% -7.07%
Insmed 20.89 1.17 5.93% -26.70%
Ionis Pharmaceuticals 38.06 1.04 2.81% -4.66%
J&J 179.52 2.01 1.13% 6.24%
Karyopharm Therapeutics 4.73 0.22 4.88% -55.00%
Ligand Pharmaceuticals 90.58 1.36 1.52% -32.02%
Merck & Co 92.42 1.25 1.37% 17.58%
Marinus Pharmaceuticals 4.76 -0.08 -1.65% -74.73%
Neurocrine Biosciences 99.25 1.77 1.82% 0.65%
Novartis 80.96 -0.69 -0.85% -4.25%
Novavax 57.15 5.72 11.12% -73.69%
Pfizer 52.31 -0.12 -0.23% 31.66%
PTC Therapeutics 41.85 1.79 4.47% -2.88%
Roche Holding 321.00 -1.60 -0.50% -9.19%
Sarepta Therapeutics 75.71 0.75 1.00% 0.62%
Vertex Pharmaceuticals 287.32 5.53 1.96% 43.27%
Immunic Inc. 3.47 0 0% -73.89%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%
US2000 1728 19.77 1.16% -25.07%

Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. is a biotechnology company. The Company uses chemistry-driven approach and drug discovery capabilities. The Company is focused on discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The Company has clinical candidates for the disease targets, including respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). It also conducts research in human metapneumovirus (hMPV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or coronavirus disease-2019 (COVID-19). The Company has discovered glecaprevir, a protease inhibitor discovered and developed through its collaboration with AbbVie for the treatment of chronic hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie’s direct-acting antiviral (DAA), a combination treatment for HCV infection under the tradenames: MAVYRET and MAVIRET.